High prevalence of frailty in patients with adrenal adenomas and adrenocortical hormone excess: a cross-sectional multi-centre study with prospective enrolment
European Journal of Endocrinology · 2023
DOI: 10.1093/ejendo/lvad113 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Journal of Endocrinology, 2023. Verfasst von Prerna Dogra und 19 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Diabetes, Metabolism and Nutrition, Mayo Clinic, Rochester, MN 55905, United States. Hauptthemen laut MEDLINE: Frailty, Adrenocortical Adenoma, Cushing Syndrome, Adenoma. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NIA NIH HHS, NIH HHS.
Themen: Gerontologische Pflege
Abstract (Originalsprache)
Objective
Frailty, characterized by multi-system decline, increases vulnerability to adverse health outcomes and can be measured using Frailty Index (FI). We aimed to assess the prevalence of frailty in patients with adrenal disorders (based on hormonal sub-type) and examine association between FI and performance-based measures of physical function.
Design
Multi-centre, cross-sectional study (March 2019-August 2022).
Methods
Adult patients with adrenal disorders (non-functioning adrenal adenomas [NFA], mild autonomous cortisol secretion [MACS], Cushing syndrome [CS], primary aldosteronism [PA]) and referent subjects without adrenal disorders completed a questionnaire encompassing 47 health variables (comorbidities, symptoms, daily living activities). FI was calculated as the average score of all variables and frailty defined as FI ≥ 0.25. Physical function was assessed with hand grip, timed up-and-go test, chair rising test, 6-minute walk test, and gait speed.
Results
Compared to referent subjects (n = 89), patients with adrenal disorders (n = 520) showed increased age, sex, and body mass index-adjusted prevalence of frailty (CS [odds ratio—OR 19.2, 95% confidence interval—CI 6.7-70], MACS [OR 12.5, 95% CI 4.8-42.9], PA [OR 8.4, 95% CI 2.9-30.4], NFA [OR 4.5, 95% CI 1.7-15.9]). Prevalence of frailty was similar to referent subjects when post-dexamethasone cortisol was <28 nmol/L and was higher when post-dexamethasone cortisol was 28-50 nmol/L (OR 4.6, 95% CI 1.7-16.5). FI correlated with all measures of physical function (P < .001).
Conclusions
Whilst frailty prevalence was highest in patients with adrenocortical hormone excess, even patients with NFA demonstrated an increased prevalence compared to the referent population. Future longitudinal studies are needed to evaluate the impact of various management strategies on frailty.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Endocrinology, Diabetes, Metabolism and Nutrition, Mayo Clinic, Rochester, MN 55905, United States.
- Department of Internal Medicine, General Hospital Koprivnica, Zeljka Selingera 1, 48000, Koprivnica, Croatia.
- Division of Endocrinology, Diabetes, Bone and Mineral Disorders, Henry Ford Health System, Detroit, MI 48202, United States.
- Department of Endocrinology, Diabetes and Metabolism, Evangelismos Hospital, 45 Ipsilantou Street, Athens 106 76, Greece.
- Department of Interna Medicine, UT Southwestern Medical Center, Dallas, TX 75390, United States.
- Division of Endocrinology and Molecular Medicine, Medical College of Wisconsin, Milwaukee, WI 53210, United States.
ORCID-Profile: Prerna Dogra, Shobana Athimulam, Natalia Genere, Irina Bancos
Förderung
- NIDDK NIH HHS
- NIA NIH HHS
- NIH HHS
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Institute of Aging
- National Institutes of Health
Zitieren
APA
Dogra, P., Šambula, L., Saini, J., Thangamuthu, K., Athimulam, S., Delivanis, D. A., Baikousi, D. A., Nathani, R., Zhang, C. D., Genere, N., Salman, Z., Turcu, A. F., Ambroziak, U., Garcia, R. G., Achenbach, S. J., Atkinson, E. J., Singh, S., LeBrasseur, N. K., Kastelan, D., & Bancos, I. (2023). High prevalence of frailty in patients with adrenal adenomas and adrenocortical hormone excess: a cross-sectional multi-centre study with prospective enrolment. European Journal of Endocrinology. https://doi.org/10.1093/ejendo/lvad113
Vancouver
Dogra P, Šambula L, Saini J, Thangamuthu K, Athimulam S, Delivanis DA, et al. High prevalence of frailty in patients with adrenal adenomas and adrenocortical hormone excess: a cross-sectional multi-centre study with prospective enrolment. European Journal of Endocrinology. 2023. doi:10.1093/ejendo/lvad113
BibTeX
@article{Dogra2023,
author = {Dogra, Prerna and Šambula, Lana and Saini, Jasmine and Thangamuthu, Karthik and Athimulam, Shobana and Delivanis, Danae A and Baikousi, Dimitra A and Nathani, Rohit and Zhang, Catherine D and Genere, Natalia and Salman, Zara and Turcu, Adina F and Ambroziak, Urszula and Garcia, Raul G and Achenbach, Sara J and Atkinson, Elizabeth J and Singh, Sumitabh and LeBrasseur, Nathan K and Kastelan, Darko and Bancos, Irina},
title = {High prevalence of frailty in patients with adrenal adenomas and adrenocortical hormone excess: a cross-sectional multi-centre study with prospective enrolment},
journal = {European Journal of Endocrinology},
year = {2023},
doi = {10.1093/ejendo/lvad113}
}
EUVIMED